Dillon Cockrell, GU Medical Oncologist at Duke Cancer Institute, shared a post on LinkedIn:
“In the last couple of weeks, we reached a new milestone by enrolling patients on our first Duke Raleigh Cancer Center Phase 1 oncology clinical trial.
The study is a first-in-human trial evaluating a novel therapy for patients with metastatic castration-resistant prostate cancer. As the site PI, I’m most excited about what this represents for patients: bringing early-phase clinical trials closer to home in their community without requiring long travel days to a larger academic campus…